{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:23Z","timestamp":1790310383336,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Curcumin and Qing Dai (QD) are herbal extracts that recently showed efficacy in treating inflammatory bowel disease (IBD). Since 2016, a combination of curcumin with QD (CurQD) has been employed in our center for management of active ulcerative colitis (UC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We report the effectiveness and safety of CurQD therapy in children with mild-moderate UC or IBD-unclassified (IBD-U).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A multicenter retrospective study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children aged\u2009\u2264OP18 years who were treated with CurQD during 2017\u20132021 were included. Disease activity measures were Pediatric UC Activity Index (PUCAI), and fecal calprotectin (FC). The primary outcome was a decrease in PUCAI by \u226510 points, FC normalization (\u2264100\u2005\u00b5g\/gr when baseline \u2265300\u2005\u00b5g\/gr) or a\u2009\u2265\u200950% decrease in FC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 30 patients (60% males, mean age 14\u2009\u00b1\u20093.9 years), 15 (50%), 13 (43%), and 2 (7%) had pancolitis, left-sided colitis and proctitis, respectively. The daily medication dose was 0.5\u20133\u2005gm QD with 1\u20134\u2005gm curcumin. Concomitant treatment at induction was corticosteroids (19%), biologics (28%) and 5-aminosalicylic acid (40%). The mean duration of induction was 11.6 weeks [95% confidence interval (CI) 10.2\u201313.1, range 8\u201316]. PUCAI decreased from a mean of 31.3 (95% CI 26.6\u201336.0, range 5\u201360) to 10.9 (95% CI 7.6\u201314.4, range 5\u201335) (<jats:italic>n<\/jats:italic>\u2009=\u200926, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). FC response and normalization occurred in 11\/12 and 7\/12 patients, respectively. The median decline in FC was from 749\u2005\u00b5g\/gm [interquartile range (IQR) 566\u20131000] to 39\u2005\u00b5g\/gm (IQR 12\u2013132) (<jats:italic>n<\/jats:italic>\u2009=\u200915, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). During follow-up (median 8 months, IQR 6\u201310), 10 patients (33%) flared; five of them regained remission or responded to a treatment change. Of 18 patients treated beyond induction, 12 (67%) achieved clinical response and 10 achieved clinical remission by the end of follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CurQD may be effective and safe as an add-on option to conventional management, for induction and maintenance in children with mild-moderate UC\/IBD-U.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1342656","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:41:13Z","timestamp":1727440873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy of curcumin\/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Nurit Loberman","family":"Nachum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Yerushalmy-Feler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dotan","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Granot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","article-title":"Biologic therapy for ulcerative colitis","volume":"49","author":"Bhattacharya","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamadermatol.2014.5460","article-title":"A Chinese herb, indigo naturalis, extracted in oil (Lindioil) used topically to treat psoriatic nails: a randomized clinical trial","volume":"151","author":"Lin","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/bjd.16807","article-title":"A traditional Chinese remedy points to a natural skin habitat: indirubin (indigo naturalis) for psoriasis and the malassezia metabolome","volume":"179","author":"Gaitanis","year":"2018","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00535-016-1292-z","article-title":"Indigo naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation","volume":"52","author":"Kawai","year":"2017","journal-title":"J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archderm.144.11.1457","article-title":"Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis","volume":"144","author":"Lin","year":"2008","journal-title":"Arch Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3748\/wjg.v19.i17.2718","article-title":"Therapeutic efficacy of the qing Dai in patients with intractable ulcerative colitis","volume":"19","author":"Suzuki","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000444217","article-title":"Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study","volume":"93","author":"Sugimoto","year":"2016","journal-title":"Digestion"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2015.02.019","article-title":"Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial","volume":"13","author":"Lang","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.cgh.2006.08.008","article-title":"Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial","volume":"4","author":"Hanai","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/apt.17538","article-title":"Real-world experience with curcumin-QingDai combination for patients with active ulcerative colitis: a retrospective multicentre cohort study","volume":"58","author":"Yanai","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000526646","article-title":"Curcumin-QingDai combination as treatment for moderate-severe ulcerative colitis","volume":"16","author":"Ben-Horin","year":"2022","journal-title":"Case Rep Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cgh.2023.05.023","article-title":"Curcumin-QingDai combination for patients with active ulcerative colitis: a randomized double-blinded placebo-controlled trial","volume":"22","author":"Ben-Horin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: from biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1053\/j.gastro.2017.11.024","article-title":"Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis","volume":"154","author":"Naganuma","year":"2018","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1253\/circj.CJ-19-1112","article-title":"Effect of oral qing-Dai medication on pulmonary arterial pressure levels in patients with ulcerative colitis","volume":"84","author":"Orihara","year":"2020","journal-title":"Circ J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1253\/circj.CJ-20-0621","article-title":"Risk of pulmonary arterial hypertension during qing-Dai use for the treatment of ulcerative colitis","volume":"84","author":"Adachi","year":"2020","journal-title":"Circ J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e15113","DOI":"10.1111\/ped.15113","article-title":"Qing-Dai for pediatric ulcerative colitis multicenter survey and systematic review","volume":"64","author":"Kudo","year":"2022","journal-title":"Pediatr Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040484","article-title":"Curcumin and its modified formulations on inflammatory bowel disease (IBD): the story so far and future outlook","volume":"13","author":"Karthikeyan","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1342656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T13:05:11Z","timestamp":1727701511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1342656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":22,"alternative-id":["10.3389\/fped.2024.1342656"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1342656","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"article-number":"1342656"}}